The drug is a joint venture between Bayer Healthcare Pharmaceuticals and Johnson & Johnson. Johnson & Johnson has applied for approval for short-term use of the drug in the prevention of deep-vein thrombosis and pulmonary embolism in patients undergoing total hip and knee replacement surgery.
The company has recently finished clinical trials on the longer-term use of rivaroxaban in patients with acute coronary syndrome.
Read about the FDA panel’s recommendation to approve rivaroxaban.
